Mazda Motor Corporation's global vehicle production saw a significant rebound in December 2025, offering a positive end to a year where overall output and sales declined. The recovery was driven by strong domestic performance and a mixed picture overseas.
As global markets navigate a period of uncertainty, a select group of technology companies across Norway, Sweden, and Israel are posting explosive growth. We examine the financials and strategies behind Appear ASA, Hacksaw AB, and NextVision Stabilized Systems—firms turning innovation into investor returns.
Takeda Pharmaceutical raises its FY2025 revenue and profit guidance following resilient nine-month results and announces U.S. availability of a new ready-to-use immunoglobulin therapy for primary immunodeficiency, fueling discussions on its growth strategy amid high debt and margin pressures.
The UK's economic recovery faces a significant drag from recently implemented fiscal tightening, with growth forecasts remaining subdued for the coming year, according to a leading economic forecaster.
As markets look ahead to 2026, a mix of established giants and emerging players in AI and digital advertising present compelling opportunities for investors seeking both growth and value.
Amidst a patchy economic recovery, European small-cap stocks are back in focus. A surge in insider buying activity points to potential undervaluation in select names across property, cybersecurity, and defense tech sectors.
Standex International's fiscal Q2 results showcase robust organic growth and record order intake, driven by a multi-year strategic pivot towards new product innovation and high-growth markets like grid infrastructure and defense.
The consumer goods giant reported stronger-than-expected Q4 results, citing growth across key metrics despite inflationary pressures. As it rolls out its ambitious 2030 growth plan, management warns of a volatile global operating environment in the year ahead.
Future Proof Brands, maker of the popular ready-to-drink brand BeatBox, is laying off over 150 employees at its headquarters. The move comes weeks after announcing a $490 million majority stake acquisition by Anheuser-Busch, signaling corporate restructuring ahead of the deal's expected close in early 2026.
Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Selective Insurance Group reported robust profitability and investment returns for 2025, driven by disciplined underwriting actions. While celebrating an 18% book value growth, management detailed significant reserve strengthening in commercial auto and outlined a confident outlook for 2026, the year of its centennial.
Compass Point initiates coverage on Orchid Island Capital (ORC) with a Neutral rating, citing concerns that the REIT's high dividend payouts could constrain its per-share book value appreciation despite its current undervaluation.
Europe relies on China for the rare earth elements essential in transition technologies, but it's making a late bid to end dependency.
The German sportswear giant reports preliminary figures showing robust growth for the Adidas brand, driven by double-digit expansion across all regions, and unveils a major capital return program to shareholders.
With the Federal Reserve holding rates steady and economic signals mixed, investors are looking beyond the S&P 500 for growth. We analyze three under-the-radar companies—Tiptree, Slide Insurance, and Colony Bankcorp—that show strong fundamentals and strategic momentum as we head into 2026.
Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
Despite a recent price target cut by KeyBanc, On Holding AG (NYSE: ONON) remains a top growth pick for 2026, with Goldman Sachs upgrading the stock to Buy. Analysts highlight the brand's global momentum and product strength as key drivers.
As the STOXX Europe 600 grapples with volatility, some investors are turning their gaze to smaller, often overlooked companies. We examine three European penny stocks, each with a market capitalization exceeding €10 million, assessing their potential amidst a challenging macroeconomic backdrop.
As European indices face headwinds, a select group of small-cap companies are seeing executives put their own money on the line. We examine three firms where insider buying signals conviction amidst broader uncertainty.
